(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2(Date:10/12/2008)...ures thin struts designed for more uniform drug ...ss., and WASHINGTON, Oct. 12 /PRNewswire-FirstCall...oday announced comprehensive data from,the TAXUS A...tive,multi-center, single-arm, historically contr...R) Paclitaxel-Eluting Stent System in a variety of...
(Date:10/10/2008)...hylaxis Treatment with Kogenate FS Reduces the,Ris...with No Pre-Existing,Joint Damage, BERKELEY, Cali...nnounced today that the U.S. Food and Drug Adminis...h Kogenate(R) FS Antihemophilic Factor,(Recombinan...d the risk of,joint damage in patients aged 0-16 y...
(Date:10/9/2008)...n to Spread Awareness and Bring Hope to Millions,o...e-USNewswire/ -- 133 million children,across the g...as natural,disaster, civil war, and disease. SOS C...d Orphan Week by calling attention to the needs of...Release, go to:, http://www.prnewswire.com/mnr/s...
(Date:10/9/2008)...Science Institute, Navigenics, Affymetrix and,Micr...EGO, Oct. 9 /- A consortium of health... forces in a first-of-its-kind,research study to a...sting,on people who choose to receive such screeni...g certain diseases., Sponsored by Scripps Transla...
Breaking Medicine Technology:Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 2Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 3Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 4Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 5Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 6FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5Photos: SOS Children's Villages Observes World Orphan Week, October 5-11, 2008 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5Open Biosystems Open Access RNAi Program Continues to Gain Momentum Worldwide 15197 1Open Biosystems Open Access RNAi Program Continues to Gain Momentum Worldwide 15197 2Open Biosystems Open Access RNAi Program Continues to Gain Momentum Worldwide 15197 3Study shows lifetime effects of pediatric liver transplants 15194 1Study shows lifetime effects of pediatric liver transplants 15194 2Next Months HR in Healthcare 28TM 29 Conference Promises to be Educational Destination for the Healthcare Industrys Senior HR Practitioners 15190 1Next Months HR in Healthcare 28TM 29 Conference Promises to be Educational Destination for the Healthcare Industrys Senior HR Practitioners 15190 2Next Months HR in Healthcare 28TM 29 Conference Promises to be Educational Destination for the Healthcare Industrys Senior HR Practitioners 15190 3Caring com Adds Vice President of Business Development 15185 1Caring com Adds Vice President of Business Development 15185 2... with Clinical HbA1c,Reductions Observed in Phase ...LO ALTO, Calif., July 9, 2007 /PRNewswire-FirstCal...esearchers have completed,preliminary preclinical ...stimulated insulin secretion in pancreatic beta ce...els of insulin,resistance, ranolazine also improve...
...- Portola,Pharmaceuticals, Inc. announced positive... oral Factor Xa inhibitor, today at the XXI,Congre...Haemostasis,(ISTH) in Geneva, Switzerland. The EXP...e, and well tolerated for the,prevention of venous...g total knee replacement (TKR) surgery. Portola ex...
Other Medicine Technology:CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of,Action for Ranexa 2CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of,Action for Ranexa 3Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 2Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 3Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 4This unique blanket is designed to be used for many surgical procedures, including but not limited to: laminectomies, spinal procedures, abdominal procedures, and transplants.
The chest access blanket is designed specifically for the thoracic surgery patient.
The cardiac access blanket helps maintain normothermia and allows unrestricted access to the patient.
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces
Medicine Products: